INTERPRETATION OF RESULTS OBTAINED IN A DOUBLE BLIND TEST MADE IN THE GENERAL HOSPITAL MEXICO WITH THE PRODUCT LIVER SUPPORT ON PATIENTS HAVING CHRONIC ALCOHOLIC HEPATIC DISEASE.
DR. CHARLES COCHRAN
1st Double Blind Study
In order to analyze carefully the results of this study, it is necessary to know the importance of the two clinical and laboratory parameters intervening in the calculations of Orrego and Maddrey Indexes. We will compare the results of the parameters, the placebo control and the Liver Support groups on both indexes. The results are presented as percentages of recovery and are obtained from the data obtained from each group of 30 patients; we will get an average of those results at the beginning and at the end of the study. Both averages will give us a final recovery compared to the initial values. This way we may demonstrate the effectiveness of Liver Support.
DEFINTIONS AND RESULTS OF PARAMETERS
ASCITES- Effusion and accumulation of serous fluid in the abdominal cavity. The experimental group (Liver Support) experienced a 28.8% reduction of ascites while the placebo group experienced no change.
ENCEPHALOPATHY- a DEGENERATIVE DISEASE OF THE BRAIN. Hepatic encephalopathy- a condition usually occurring secondarily to advanced disease of the liver. It is marked by disturbances of consciousness that may progress to deep coma (hepatic coma) psychiatric changes of varying degree, flapping tremor and fetor hepaticas. Also called portal-systemic encephalopathy. Patients on Liver Support experienced a 34.55% reduction of hepatic encephalopathy. The placebo group experienced a 5.5% reduction.
SPLENOMEGALIA- Enlargement of the spleen. An 18.18% reduction was observed in the Liver Support group and a 55% reduction was observed in the placebo group.
WEAKNESS- Lacking physical strength or vigor marked by asthenia atony cardiasthena enervation fatigue and lassitude. The Liver Support group experienced an 83.45% decrease in the incidence of weakness while the placebo group reported no change.
PERIPHERAL EDEMA- A condition in which the body tissues contain an excess amount of fluid. The Liver Support Group experienced an 11.10% reduction in peripheral edema while the placebo group had a 0.69% reduction.
HEMORRHAGES- Bleeding. This was one of the most important benefits observed in the Liver Support group. The Liver Support group had an 89.41% reduction in hemorrhages while the placebo had a 31% reduction.
ANOREXIA- Loss of appetite. Seen in depression malaise commencement of fevers and illness also in disorders of the alimentary tract especially of the stomach and as a result of alcoholic excess and drug addiction. Anorexia was diminished by 86.07% in the Liver Support group. There was no change in the placebo group.
TOTAL BILIRUBIN LEVEL - The predominant pigment of human bile. Total serum bilirubin may be increased in cirrhosis of the liver and acute viral hepatitis. The Liver Support group obtained 25.11% reduction in bilirubin whereas the placebo group had a 7.2% increase.
OGT - (Oxalacetic Glutamic Transaminase). It is distributed all over body tissue especially in the heart and liver. Less amounts are found in the spleen pancreas kidneys lungs and brain. Any lesion of a tissue leads to the secretion of this enzyme to the blood stream. The activity of OGT is risen under hepatic necrosis cirrhosis of the liver or hepatic metastasis. In those patients who received Liver Support this level diminished 22.56% in only 15 days of treatment and in the placebo group it diminished 8.51%.
PROTHROMBINE TIME - A test of clotting time made by determining the time for clotting to occur after thromboplastin and calcium are added to decalcified plasma. There was 30.82% reduction in prothrombin time for Liver Support patients whereas the placebo group's time increased 1.25%. This is very important data because it means that Liver Support helps the healing of wounds faster.
SERUM ALBUMIN - One of a group of simple proteins widely distributed in tissues. Albumin is a constituent of blood. Low levels of albumin in blood plasma are associated with a pathologic condition of the liver. The Liver Support group experienced an increase of 8.85% of total albumin levels while the placebo group experienced a 5.35% increase.
Article published about Extreme's Liver Support Formula in:
"THE TOWNSEND LETTER for DOCTOR'S PATIENTS"
HEPATITIS LIVER CIRRHOSIS/HCC
Increasing Evidence Suggest Extreme Health's Liver Support Formula may be Effective in Compromising the Detrimental Effects of Hepatitis-Engendered Cirrhosis.
HEPATITIS LIVER CIRRHOSIS/HCC Read complete article click here